Feb 19, 2023
Harold Punnett DMD, co-founder, NervGen Pharma Corp describes the origins of the business as ‘a story of tragedy, a hope and a dream, and one for which the end is yet to be written’ in Jan Cavelle’s new book: Start for Success: The Entrepreneur’s Guide to Start-Ups is available at Amazon.com in Canada, the United States, United Kingdom and Australia.
New book by Jan Cavelle includes feature interview with NervGen co-founder, Dr. Harold Punnett
NervGen (TSX-V: NGEN, OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in the company’s initial target indication, spinal cord injury. NervGen has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury.
Contact
112-970 Burrard Street
Unit 1290
Vancouver, BC V6Z 2R4
Phone: (778) 731-1711
Email: info@nervgen.com
